Pharma & Biotech
Bayer’s Dual Narrative: A Crop Science Endorsement Meets a Pharma Pipeline Rebuttal
The investment case for Bayer is increasingly being written on two separate pages. While Wall Street's attention has gravitated toward...
Ocugen’s OCU410 Trial Now Recruiting — But the Verdict Is Still Two Years Away
The first patient has been dosed in Ocugen's global Phase 3 registration study for OCU410, the company's one-time gene therapy...
Novo Nordisk’s Oral Push Marks a Sales Milestone as Trial Setbacks and Rival Pressure Keep the Spotlight on the Pipeline
Novo Nordisk is getting one piece of good news that is easy to count: Wegovy has now passed five million...
Milan Fertility Clinic Suspended After Embryo Mix-Up Sparks Safety Reforms Across Europe
The moment a surgical team realized what had happened, the procedure was already over. A woman at Milan's Ospedale San...
Novo Nordisk Faces a Harder Sell as Forecasts, Trials and Rivalry All Tighten
Novo Nordisk may have delivered a quarter that looked respectable on paper, but the market’s verdict was harsher. In a...
Bayer’s results beat, debt eases and legal strategy gains traction
Bayer’s latest update arrived with several moving parts at once: better-than-expected quarterly earnings, a lower debt outlook and fresh confirmation...
BioNTech’s leadership handover arrives just as guidance tightens
BioNTech is entering a stretch where the story is being reshaped on two fronts at once: the numbers and the...
Spero Therapeutics Pivots Away From Infectious Disease as Shares Sink to Historic Lows
The market has delivered a brutal verdict on Spero Therapeutics' corporate reinvention. Shares in the biotech group have tumbled roughly...
Alnylam’s Profitability Milestone Collides With a Guidance Cut — and Investors Bolt
There is a peculiar arithmetic at work in Alnylam Pharmaceuticals' stock right now: the company just delivered its first-ever quarterly...
Bayer’s Long Shadow Finally Lifts: Legal Breakthrough and a Defining Week for the DAX’s Comeback Story
The narrative that has defined Bayer for half a decade is finally shifting. For years, the chemicals-to-pharma group was the...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
